Eurofins Scientific SE Stock
Stocks
ERF
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
After hours 04:00:00 | |||
| 69.00 EUR | -0.72% |
|
68.27 | -1.06% |
| 06-30 | NFL Biosciences validates industrial-scale production of NFL-102 for smoking cessation |  |
| 06-05 | Eurofins Scientific SE acquired High North Laboratories. | CI |
| Market Cap | 12.06B 13.8B 11.15B 10.3B 19.39B 1,325B 19.74B 133B 52.15B 649B 51.83B 50.68B 2,235B | P/E 2026 * |
24.1x | P/E 2027 * | 18.5x |
|---|---|---|---|---|---|
| Enterprise Value | 15.5B 17.74B 14.33B 13.24B 24.93B 1,704B 25.38B 171B 67.04B 834B 66.62B 65.15B 2,872B | EV / Sales 2026 * |
2.04x | EV / Sales 2027 * | 1.88x |
| Free-Float |
58.35% | Yield 2026 * |
1.11% | Yield 2027 * | 1.29% |
Last Transcript: Eurofins Scientific SE
| 1 day | -0.72% | ||
| 1 week | +0.44% | ||
| Current month | +0.64% | ||
| 1 month | +7.68% | ||
| 3 months | +6.32% | ||
| 6 months | -5.63% | ||
| Current year | +10.58% |
| 1 week | 66.6 |  | 69.94 |
| 1 month | 61.44 | | 70.28 |
| Current year | 56.84 | | 74.32 |
| 1 year | 54.86 | | 74.32 |
| 3 years | 39.47 | | 74.32 |
| 5 years | 39.47 | | 127.68 |
| 10 years | 29.82 | | 127.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 01/01/1987 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 01/01/2015 |
Christian Wurst
PRN | Corporate Officer/Principal | 53 | 01/10/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 01/01/1987 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 01/01/2015 |
Valérie Hanote
BRD | Director/Board Member | 60 | 01/01/1990 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 04-27 | Buy | 700 | 0.0004% | |||
| 04-19 | Sell | Chief Financial Officer | 3,000 | 0.0016% | ||
| 04-19 | Fiscal year | Executive/Senior Manager | 700 | 0.0004% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.72% | +0.44% | +13.86% | +16.48% | 13.85B | |
| -1.05% | +0.34% | +3.26% | +9.64% | 50.61B | |
| +0.55% | -2.88% | +382.07% | +593.81% | 39.11B | |
| +0.13% | -0.19% | +29.79% | -6.00% | 34.64B | |
| +0.86% | -0.78% | +21.58% | +56.15% | 33.79B | |
| -1.31% | -1.76% | +1.59% | +27.01% | 26.89B | |
| +0.13% | -0.52% | - | - | 16.47B | |
| +1.13% | -1.85% | +67.36% | +120.46% | 15.14B | |
| +1.13% | -0.44% | +12.34% | -31.79% | 12.72B | |
| -1.17% | -7.91% | +1,569.48% | +638.18% | 11.8B | |
| Average | +0.03% | -2.07% | +233.48% | +158.21% | 25.5B | |
| Weighted average by Cap. | +0.01% | -1.40% | +154.28% | +148.00% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.6B 8.7B 7.03B 6.49B 12.22B 835B 12.44B 83.78B 32.87B 409B 32.67B 31.94B 1,408B | 8.07B 9.24B 7.46B 6.9B 12.99B 887B 13.22B 89.01B 34.92B 435B 34.7B 33.94B 1,496B |
| Net income | 517M 591M 478M 441M 831M 56.79B 846M 5.7B 2.23B 27.81B 2.22B 2.17B 95.75B | 676M 774M 625M 577M 1.09B 74.32B 1.11B 7.45B 2.92B 36.39B 2.91B 2.84B 125B |
| Net Debt | 3.44B 3.94B 3.18B 2.94B 5.54B 378B 5.64B 37.95B 14.89B 185B 14.79B 14.47B 638B | 3.08B 3.53B 2.85B 2.63B 4.96B 339B 5.05B 34B 13.34B 166B 13.26B 12.97B 572B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/07/26 | €69.00 | -0.72% | 225,880 |
| 13/07/26 | €69.50 | +0.78% | 151,866 |
| 10/07/26 | €68.96 | +0.23% | 233,361 |
| 09/07/26 | €68.80 | +2.59% | 280,414 |
| 08/07/26 | €67.06 | -2.70% | 226,836 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ERF Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
